Cardiome Pharma Corp enters Commercialization agreement with Aspen for Brinavess in South Africa
Monday, November 17, 2014
Cardiome Pharma Corp. today announced that an affiliate of the company has entered into an agreement with Pharmacare Limited, which trades as Aspen Pharmacare and is a part of the Aspen Group, to sell and distribute BRINAVESS® (vernakalant intravenous) exclusively in South Africa. Under the terms of the agreement, Aspen has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement have not been disclosed.
“We are pleased to expand our commercial agreement with Aspen to now include BRINAVESS in South Africa,” said Karim Lalji, Cardiome’s Chief Commercial Officer. “Aspen has proven to be a valuable partner to Cardiome through their commercialization efforts behind AGGRASTAT®. This will be the first country in Africa where BRINAVESS will be launched and we remain committed to making this drug available to all our customers worldwide.”
“It is exciting for us to expand our portfolio to now include BRINAVESS alongside Cardiome’s AGGRASTAT,” said Noel Guliwe, CEO at Aspen Pharmacare, South Africa. “We are looking forward to making it available to all of our hospital customers throughout the country.”
In 2014, the South African pharmaceutical market was estimated to be valued at ZAR 30.6.
Source : http://www.cardiome.com/
